• Pulmonary hypertension, part 3: Early therapies and vascular physiology

  • 2025/03/25
  • 再生時間： 48 分
  • ポッドキャスト

Pulmonary hypertension, part 3: Early therapies and vascular physiology

無料で聴く

ポッドキャストの詳細を見る

  • サマリー

  • In this episode, we dive into the early therapies and how our understanding of vascular physiology drastically changed the management of pulmonary hypertension.

    • Intro 0:12
    • In this episode 0:18
    • Recap of part 1 & 2 0:31
    • What part 3 is about 2:31
    • WHO conference in 1975: Treating pulmonary hypertension 3:48
    • The Discovery of Non-Steroidal Anti-inflammatory Drugs (NSAIDs), Part 1 5:20
    • Epoprostenol 6:18
    • Prostacyclin 10:37
    • Endothelin antagonists 11:41
    • Phosphodiesterase type 5 (PDE5) inhibitors 14:08
    • Interaction of nerves and blood vessels 15:06
    • The Soups VS the Sparks 17:36
    • A dreamed experiment 19:06
    • Acetylcholine 23:23
    • Enter “the calabar bean” 24:45
    • Acetylcholine and vasodilation: 1976 26:01
    • Rabbit aorta 27:45
    • Nitric oxide 29:38
    • Why are we using nitric oxide to treat pulmonary hypertension? 31:31
    • Tachyphylaxis 33:48
    • TNT factories 35:09
    • Nitrous oxide and tachyphylaxis 36:52
    • Pfizer in the 1980s 38:06
    • Understanding the trigger of pulmonary hypertension 40:53
    • PDE5 and nitric oxide and pulmonary hypertension 43:07
    • The end of the ripping yarns 44:20
    • Coming up in part 4 46:17
    • Thanks for listening 47:29

    We’d love to hear from you! Send your comments/questions to Dr. Brown at rheuminationspodcast@healio.com. Follow us on Twitter @HRheuminations @AdamJBrownMD @HealioRheum.

    References:
    Bernard C. C R Soc Biol. 1851;3:163-164.
    Furchgott RF, et al. Nature. 1980;doi:10.1038/288373a0.
    Galiè N, et al. N Engl J Med. 2005;doi:10.1056/NEJMoa050010.
    Ghofrani HA, et al. Nat Rev Drug Discov. 2006;doi:10.1038/nrd2030.
    Giordano D, et al. Biochim Biophys Acta. 2001;doi:10.1016/s0167-4889(01)00086-6.
    Guthrie F. Q J Chem Soc. 1859;doi:10.1039/QJ8591100245.
    Higenbottam T, et al. Lancet. 1984;doi:10.1016/s0140-6736(84)91452-1.
    Marsh N, et al. Clin Exp Pharmacol Physiol. 2000;doi:10.1046/j.1440-1681.2000.03240.x.
    Montastruc JL, et al. Clin Auton Res. 1996;doi:10.1007/BF02281906.
    Nejad SH, et al. Future Cardiol. 2024;doi:10.1080/14796678.2024.2367390.
    Tansey EM. C R Biol. 2006;doi:10.10116/j.crvi.2006.03.012.
    Warren JV. Trans Am Clin Climatol Assoc. 1988;99:10-6.

    Disclosures: Brown reports no relevant financial disclosures.
    続きを読む 一部表示

あらすじ・解説

In this episode, we dive into the early therapies and how our understanding of vascular physiology drastically changed the management of pulmonary hypertension.

  • Intro 0:12
  • In this episode 0:18
  • Recap of part 1 & 2 0:31
  • What part 3 is about 2:31
  • WHO conference in 1975: Treating pulmonary hypertension 3:48
  • The Discovery of Non-Steroidal Anti-inflammatory Drugs (NSAIDs), Part 1 5:20
  • Epoprostenol 6:18
  • Prostacyclin 10:37
  • Endothelin antagonists 11:41
  • Phosphodiesterase type 5 (PDE5) inhibitors 14:08
  • Interaction of nerves and blood vessels 15:06
  • The Soups VS the Sparks 17:36
  • A dreamed experiment 19:06
  • Acetylcholine 23:23
  • Enter “the calabar bean” 24:45
  • Acetylcholine and vasodilation: 1976 26:01
  • Rabbit aorta 27:45
  • Nitric oxide 29:38
  • Why are we using nitric oxide to treat pulmonary hypertension? 31:31
  • Tachyphylaxis 33:48
  • TNT factories 35:09
  • Nitrous oxide and tachyphylaxis 36:52
  • Pfizer in the 1980s 38:06
  • Understanding the trigger of pulmonary hypertension 40:53
  • PDE5 and nitric oxide and pulmonary hypertension 43:07
  • The end of the ripping yarns 44:20
  • Coming up in part 4 46:17
  • Thanks for listening 47:29

We’d love to hear from you! Send your comments/questions to Dr. Brown at rheuminationspodcast@healio.com. Follow us on Twitter @HRheuminations @AdamJBrownMD @HealioRheum.

References:
Bernard C. C R Soc Biol. 1851;3:163-164.
Furchgott RF, et al. Nature. 1980;doi:10.1038/288373a0.
Galiè N, et al. N Engl J Med. 2005;doi:10.1056/NEJMoa050010.
Ghofrani HA, et al. Nat Rev Drug Discov. 2006;doi:10.1038/nrd2030.
Giordano D, et al. Biochim Biophys Acta. 2001;doi:10.1016/s0167-4889(01)00086-6.
Guthrie F. Q J Chem Soc. 1859;doi:10.1039/QJ8591100245.
Higenbottam T, et al. Lancet. 1984;doi:10.1016/s0140-6736(84)91452-1.
Marsh N, et al. Clin Exp Pharmacol Physiol. 2000;doi:10.1046/j.1440-1681.2000.03240.x.
Montastruc JL, et al. Clin Auton Res. 1996;doi:10.1007/BF02281906.
Nejad SH, et al. Future Cardiol. 2024;doi:10.1080/14796678.2024.2367390.
Tansey EM. C R Biol. 2006;doi:10.10116/j.crvi.2006.03.012.
Warren JV. Trans Am Clin Climatol Assoc. 1988;99:10-6.

Disclosures: Brown reports no relevant financial disclosures.
続きを読む 一部表示

Pulmonary hypertension, part 3: Early therapies and vascular physiologyに寄せられたリスナーの声

カスタマーレビュー：以下のタブを選択することで、他のサイトのレビューをご覧になれます。

Audible.co.jp

Amazon.co.jp
レビューはまだありません。